SARS-CoV-2 Vaccine Protection and Deaths Among US Veterans During 2021

Overview

Journal Science

Specialty Science

Date 2021 Nov 4

PMID 34735261

Citations 139

Authors

Barbara A Cohn

Piera M Cirillo

Caitlin C Murphy

Nickilou Y Krigbaum

Arthur W Wallace

Affiliations

Soon will be listed here.

Abstract

We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine effectiveness against infection (VE-I) and death (VE-D) by vaccine type in 780,225 veterans in the Veterans Health Administration, covering 2.7% of the US population. From February to October 2021, VE-I declined for all vaccine types, and the decline was greatest for the Janssen vaccine, resulting in a VE-I of 13.1%. Although breakthrough infection increased risk of death, vaccination remained protective against death in persons who became infected during the Delta variant surge. From July to October 2021, VE-D for age <65 years was 73.0% for Janssen, 81.5% for Moderna, and 84.3% for Pfizer-BioNTech; VE-D for age ≥65 years was 52.2% for Janssen, 75.5% for Moderna, and 70.1% for Pfizer-BioNTech. Findings support continued efforts to increase vaccination, booster campaigns, and multiple additional layers of protection against infection.

Citing Articles

Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine.

Chen Z, Xie F, Zhang H, Li D, Zhang S, Zhang M Front Public Health. 2025; 13:1478627.

PMID: 39935878 PMC: 11811089. DOI: 10.3389/fpubh.2025.1478627.

Estimating the Effect of Coronavirus Disease 2019 (COVID-19) Vaccination and Infection Variant on Post-COVID-19 Venous Thrombosis or Embolism Risk.

OCarroll A, Richard S, Byrne C, Rusiecki J, Wier B, Berjohn C Open Forum Infect Dis. 2024; 11(11):ofae557.

PMID: 39494453 PMC: 11530954. DOI: 10.1093/ofid/ofae557.

Confounding and Negative Control Methods in Observational Study of SARS-CoV-2 Vaccine Effectiveness: A Nationwide, Population-Based Danish Health Registry Study.

Obel N, Fox M, Tetens M, Pedersen L, Krause T, Ullum H Clin Epidemiol. 2024; 16:501-512.

PMID: 39081306 PMC: 11287201. DOI: 10.2147/CLEP.S468572.

Frequency of SARS-COV-2 infection and COVID-19 vaccine uptake and protection among Syrian refugees : COVID-19 Vaccine among Syrian Refugees.

Altas Z, Sezerol M BMC Infect Dis. 2024; 24(1):570.

PMID: 38851672 PMC: 11161936. DOI: 10.1186/s12879-024-09460-4.

Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.

Petrovsky N Hum Vaccin Immunother. 2024; 20(1):2363016.

PMID: 38839044 PMC: 11155708. DOI: 10.1080/21645515.2024.2363016.

References

Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C . Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine. 2021; 40:101129. PMC: 8435265. DOI: 10.1016/j.eclinm.2021.101129. View

Hirschtick J, Titus A, Slocum E, Power L, Hirschtick R, Elliott M . Population-Based Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics. Clin Infect Dis. 2021; 73(11):2055-2064. PMC: 8240848. DOI: 10.1093/cid/ciab408. View

Young-Xu Y, Korves C, Roberts J, Powell E, Zwain G, Smith J . Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans. JAMA Netw Open. 2021; 4(10):e2128391. PMC: 8495523. DOI: 10.1001/jamanetworkopen.2021.28391. View

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

van den Borst B . Recovery after Covid-19. Lancet Reg Health West Pac. 2021; 12:100208. PMC: 8262450. DOI: 10.1016/j.lanwpc.2021.100208. View

Brusselaers N, Lagergren J . The Charlson Comorbidity Index in Registry-based Research. Methods Inf Med. 2018; 56(5):401-406. DOI: 10.3414/ME17-01-0051. View

Pouwels K, Pritchard E, Matthews P, Stoesser N, Eyre D, Vihta K . Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021; 27(12):2127-2135. PMC: 8674129. DOI: 10.1038/s41591-021-01548-7. View

. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(21):792-793. PMC: 8158893. DOI: 10.15585/mmwr.mm7021e3. View

Rosenberg E, Holtgrave D, Dorabawila V, Conroy M, Greene D, Lutterloh E . New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(37):1306-1311. PMC: 8445378. DOI: 10.15585/mmwr.mm7037a7. View

10.

Doria-Rose N, Suthar M, Makowski M, OConnell S, McDermott A, Flach B . Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021; 384(23):2259-2261. PMC: 8524784. DOI: 10.1056/NEJMc2103916. View

11.

Krause P, Fleming T, Peto R, Longini I, Figueroa J, Sterne J . Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021; 398(10308):1377-1380. PMC: 8437678. DOI: 10.1016/S0140-6736(21)02046-8. View

12.

Christie A, Henley S, Mattocks L, Fernando R, Lansky A, Ahmad F . Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine - United States, September 6, 2020-May 1, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(23):858-864. PMC: 8191865. DOI: 10.15585/mmwr.mm7023e2. View

13.

Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

14.

Goel R, Painter M, Apostolidis S, Mathew D, Meng W, Rosenfeld A . mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021; 374(6572):abm0829. PMC: 9284784. DOI: 10.1126/science.abm0829. View

15.

Goldberg Y, Mandel M, Bar-On Y, Bodenheimer O, Freedman L, Haas E . Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021; 385(24):e85. PMC: 8609604. DOI: 10.1056/NEJMoa2114228. View

16.

Nanduri S, Pilishvili T, Derado G, Soe M, Dollard P, Wu H . Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March.... MMWR Morb Mortal Wkly Rep. 2021; 70(34):1163-1166. PMC: 8389386. DOI: 10.15585/mmwr.mm7034e3. View

17.

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

18.

Sudre C, Murray B, Varsavsky T, Graham M, Penfold R, Bowyer R . Attributes and predictors of long COVID. Nat Med. 2021; 27(4):626-631. PMC: 7611399. DOI: 10.1038/s41591-021-01292-y. View

19.

Chemaitelly H, Yassine H, Benslimane F, Al Khatib H, Tang P, Hasan M . mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021; 27(9):1614-1621. DOI: 10.1038/s41591-021-01446-y. View

20.

Thompson M, Burgess J, Naleway A, Tyner H, Yoon S, Meece J . Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December.... MMWR Morb Mortal Wkly Rep. 2021; 70(13):495-500. PMC: 8022879. DOI: 10.15585/mmwr.mm7013e3. View